Allos Therapeutics, Inovio Biomedical, Cortegra and Genetix have all had people on the move in the world of pharmaceutical manufacturing.
Allos Therapeutics this week announced the appointment of Bruce Bennett to the position of vice president, manufacturing.
Bennett's focus in his new position will be to lead the company's manufacturing functions to support continued development and potential commercialisation of product candidates.
Since 2006, Bennett has acted as an independent consultant focused on the development of business operations, technical and supply chain solutions for biotechnology and pharmaceutical companies. Prior to this, he was vice president of manufacturing at La Jolla Pharmaceuticals, and also held positions at Provasis Therapeutics and Via Medical Corporations among others.
Inovio Biomedical has promoted Punit Dhillon to vice president of finance and operations at the US company.
The specialist in electroporation-based drug delivery announced this promotion on Wednesday, with immediate effect.
In his new role, Dhillon will take responsibility for the implementation of the firm's corporate strategy, including annual budgets and milestones.
Prior to joining Inovio five years ago, Dhillon held positions with MDS Capital (now Lumira) and was consultant to several early-stage health and life science firms.
Only a matter of weeks after announcing the appointment of two new account executives, pharma packaging specialist Cortegra has this week named John Kay as the firm's new vice president of operations.
Kay joins Cortegra from construction firm J.J. White, where he was director of corporate development and effectiveness. He also spent 15 years with packaging firm Alcoa in a number of senior operations positions.
UK firm Genetix, a developer of technologies for automated high throughput cell identification and selection for the pharma and biotech industries, has announced the appointment of Jerry Williamson as the firm's new president of US operations.
In the newly created position, Williamson will be responsible for leading the firm's commercial operations with particular focus on the US marketplace. Williamson will also serve as Genetix' global leader of diagnostic business development, responsible for establishing and executing the company's growth strategy in the diagnostic and biomarker imaging markets.
Prior to joining Genetix, Williamson held senior positions with Biacore, Pyrosequencing, Genzyme and Roche Laboratories.